Monday, May 31, 2010

Glenmark Pharmaceuticals = FY10 RESULTS = CONSOLIDATED EXCELS = STAND ALONE LACKLUSTRE




Glenmark
Pharmaceuticals Limited

Glenmark has produced mixed results in its consolidated and stand alone results for FY 10 versus FY 09.

CONSOLIDATED
RESULTS

Net Sales has increased by 119.12 percent to Rs.2485 Crores compared to Rs.1134 crores last year.
Total Expenditure        has also increased by 114.98 percent to Rs.1986 Cr in FY 10 compared to Rs.924 Cr last year.
Consol.Net Profit has increased by 146.41 percent YOY to Rs.331 Cr from Rs,134 cr last year.
Consolidated Basic EPS   has gone up to Rs.12.44 on a Face value of Rs.1/- from Rs.5.27 last year.
Thus, on consolidated basis, the results certainly represent a quantum leap over FY 09.



FY10(lakhs)
Diff%age
Net Sales
248484.55
113401.36
119.12
Other OptgIncome
2723.41
1722.08
58.15
SIT & WIP
-2914.64
165.63
-1859.73
Raw Materials
56604.31
28699.01
97.23
Traded goods
26923.26
7750.06
247.39
Employees Cost
34250.08
17020.27
101.23
Depreciation
12061.04
6740.15
78.94
Other Expenditure
71664.98
32000.61
123.95
Total Expenditure
198589.03
92375.73
114.98
Profit-Operations
52618.93
22747.71
131.32
Other Income
2172.94
1660.26
30.88
Interest
16402.13
8945.04
83.37
Tax Expense
5286.58
2028.97
160.55
Net Profit
33103.16
13433.96
146.41
Consol.Net Profit
33103.16
13433.96
146.41
Dividend (%)
-
-
Face Value (in Rs.)
1
1
0
Paid-up Equity
2698.38
2695.81
0.1
Reserves
232824.95
-
Basic EPS
12.44
5.27
136.05
Diluted EPS
12.42
5.25
136.57


NON CONSOLIDATED
RESULTS

On a stand alone basis, Net Sales has increased by just 19.48 percent to Rs.1022 Crores from Rs.855 Cr  last year.
Total Expenditure has increased more than proportionately, by 34.69 percent to Rs.879.93 Crores from last year’s Rs.653.28 Cr.
Consequently, stand alone Net Profit has come down by 41.05 percent to Rs.128.46 Crores from last year’s Net profit of Rs.217.93 Cr.
Stand alone Basic EPS has therefore taken a beating to Rs.4.93 on a face value of Rs.1/- compared to last year’s EPS of Rs.8.72.
 Thus, the stand alone results are in sharp contrast to the consolidated results for the current year.
Dividend has been maintained at 40 percent, same as last year.


FY10(lakhs)
Diff%age
Net Sales
102191.05
85529.13
19.48
Other OprtgIncome
87.13
81.46
6.96
SIT & WIP
-208.78
-1516.2
-86.23
Raw Materials
20432.18
17289.71
18.18
Traded goods
8414.96
6872.27
22.45
Employees Cost
13391.69
12983.32
3.15
Depreciation
2127.78
1910.45
11.38
Other Expenditure
43834.97
27787.96
57.75
Total Expenditure
87992.8
65327.51
34.69
Profit-Operations
14285.38
20283.08
-29.57
Other Income
831.84
9867.77
-91.57
Interest
3015.84
5513.86
-45.3
Exceptional items
-
29.8
Tax Expense
-744.94
2814.56
-126.47
Extraordinary Items
-
-
Net Profit
12846.32
21792.63
-41.05
Dividend (%)
40
40
0
Face Value (in Rs.)
1
1
0
Paid-up Equity
2698.38
2505.2
7.71
Reserves
174643.16
120491.85
44.94
Basic EPS
4.93
8.72
-43.46
Diluted EPS
4.92
8.54
-42.39


QUARTERLY
RESULTS

In respect of quarterly results, Q2,Q3 and Q4 sales are far better than earlier quarters. On Q4 of FY 09, Q4 of FY10 represents a 51% increase in sales,51 % increase in net profit and  54% increase in EPS.
Looking at the approvals, licensing arrangements etc being made by Glenmark, it is felt that the future results could be further improved on Q4 results.
However, looking at its stand alone results, vis avis the consolidated results, it appears that its Indian operations are not as strong as its foreign operations.

Mar-10
Dec-09
Dif%age
Sep-09
Jun-09
Mar-09
Dif% 2
Net Sales
28920
27691.7
4.44
23583.5
21995.9
19115.6
51.29
Total Expdr
25489.8
22746
12.06
17858.9
21898.1
17769.7
43.45
Net Profit
2825.62
3748.51
-24.62
5750.18
522
5728.44
-50.67
Dividend (%)
40
-

-
-
40
0
Face Value
1
1
1
1
1
1
0
Pd Up Equity
2698.38
2697.02
0.05
2695.81
2505.86
2505.2
7.71
Reserves
-
-

-
-
-
Basic EPS
1.05
1.39
-
2.27
0.21
2.29
-54.15


ANNOUNCEMENTS
TO EXCHANGE

28-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 28, 2010, titled "Glenmark's consolidated revenue increases by 44% to Rs.7091 Mn for Q4-FY'10. Consolidated Net Profit was at 1026 million".
28-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 70914.73 lacs for quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 10261.85 lacs for the quarter ending on 31-MAR-2010.     -
28-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange that the Board of Directors, at their meeting held on May 28, 2010, has recommended Dividend @ 40% i.e. Re.0.40 per share (face value Re.1/-) on the Equity Share Capital of the Company for the financial year 2009-2010 subject to the approval of Shareholders at the Annual General Meeting.      -
28-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 28919.98 lacs for quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 2825.62 lacs for the quarter ending on 31-MAR-2010.   -
28-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 102191.05 lacs for year ending on 31-MAR-2010 against Rs. 85529.13 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 12846.32 lacs for the year ending on 31-MAR-2010 against Rs. 21792.63 lacs for the year ending on 31-MAR-2009.      -
28-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 248484.55 lacs for year ending on 31-MAR-2010 against Rs. 209301.68 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 33103.16 lacs for the year ending on 31-MAR-2010 against Rs. 19347.29 lacs for the year ending on 31-MAR-2009. -
17-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange that Forest Laboratories Inc. USA and Glenmark Pharmaceuticals, on May 15, 2010, announced that topline results from Oglemilast (GRC 3886) did not meet the primary endpoint in its Phase IIb study on Asthma patients. Forest and Glenmark would discuss further course of action regarding Oglemilast.         -
11-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 11, 2010, titled "Glenmark & Merck settle patent litigation covering Zetia(R)".
06-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 06, 2010, titled "Glenmark Generics enters into an exclusive licensing agreement with Taro Pharmaceuticals, USA for a branded product".      
04-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 04, 2010, titled "Glenmark Generics enters into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe".
03-05-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 03, 2010, titled "Sanofi-Aventis and Glenmark Pharmaceuticals Sign License Agreement - Development of Novel Agents to treat Chronic Pain".
29-04-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 29, 2010, titled "Glenmark launches Prasugrel for the first time in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
26-04-2010        Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 26, 2010, titled "Glenmark Generics receives USFDA approval for Norethindrone tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
07-04-2010        Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 07, 2010, titled "Glenmark Generics receives UK-MA approval for Ropinirole film-coated tablets and to distribute Lercanidipine Hydrochloride film-coated tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
01-04-2010        Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 01, 2010, titled "Glenmark Generics receives approval from USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).
31-03-2010        Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 31, 2010, titled "Glenmark Generics announced New Drug Applications for Oxycodone Hydrochloride Capsules and Liquid Solution". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).
26-03-2010        Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 26, 2010, titled "Glenmark Generics receives approval from the USFDA for Calcipotriene Ointment". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements)
22-03-2010        Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its meeting held on March 22, 2010 allotted 6,100 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
18-03-2010        Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated March 18, 2010, titled " Glenmark Generics receives approval from the USFDA for Moexipril Hydrochloride Tablets". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).


*  *  *  E N D  *  *  *